Elicio reports preliminary Phase 1a data for ELI-002 7P: 100% T cell response, biomarker reductions

Elicio Therapeutics, Inc.

ELI-002 7P generated mKRAS-specific T cell response in 100% (11/11) evaluable patients; responses against all mutations enrolled.
At 4.9 mg RP2D, 66.7% (4/6) had both CD8+ and CD4+ responses; biomarker reductions in 71% (5/7) evaluable patients.
Antigen-spreading observed: T cell responses targeting non-immunizing tumor neoantigens in 100% (6/6) at RP2D.
No dose-limiting toxicities, no treatment-related serious adverse events or cytokine release syndrome.
Recommended Phase 2 dose: 4.9 mg AMP-Peptides 7P with 10 mg AMP-CpG-7909.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.